Loading
A phase 2 trial of Rituximab, Methotrexate, Procarbazine, Temozolomide, Lisocabtagene maraleucel and Fludarabine in non-Hodgkin lymphoma, run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, now recruiting.
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma is a phase 2 interventional study registered as NCT07015242 by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, with 65 participants planned, started 2025-11-06 and due to reach its primary completion in 2028-01-09. Interventions recorded: Rituximab, Methotrexate, Procarbazine, Temozolomide, Liso-cel and Fludarabine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rituximab, Bristol Myers Squibb, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Rituximab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Bristol Myers Squibb, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Fludarabine, Rituximab and the tag pipeline.
Shares Temozolomide, Bristol Myers Squibb and the tag pipeline.
Shares Fludarabine, Rituximab and the tag pipeline.
Shares Temozolomide, Bristol Myers Squibb and the tag pipeline.
Shares Rituximab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/